Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Down 39.7% in June

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the target of a large drop in short interest in June. As of June 15th, there was short interest totaling 205,707 shares, a drop of 39.7% from the May 31st total of 341,334 shares. Based on an average trading volume of 100,848 shares, the days-to-cover ratio is presently 2.0 days. Currently, 2.2% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TPST. Wall Street Zen cut Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research downgraded Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Tempest Therapeutics has an average rating of “Reduce”.

Tempest Therapeutics Stock Performance

NASDAQ TPST opened at $1.09 on Friday. The company has a market capitalization of $17.42 million, a PE ratio of -0.18 and a beta of -1.73. Tempest Therapeutics has a 52-week low of $1.02 and a 52-week high of $12.23. The company has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $2.11.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). As a group, analysts forecast that Tempest Therapeutics will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempest Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sabby Management LLC purchased a new stake in Tempest Therapeutics during the fourth quarter valued at about $513,000. Vanguard Group Inc. increased its stake in shares of Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics in the fourth quarter worth about $33,000. 22.52% of the stock is owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.